Pharma-Funded Pilot To Improve Adherence, Lower Readmissions Gets OIG Nod
Executive Summary
Medicare Advantage plans might eventually use toolkit being developed by the Academy of Managed Care Pharmacy, which is a partner in the initiative.
You may also be interested in...
Value-Based Contracts Getting More Safe Harbor Attention From OIG
But so far, OIG has declined a blanket safe harbor for proposed value-based payments, saying it still wants to consider proposals case-by-case. Discussions between the office and stakeholders are continuing, Bristol-Myers Squibb's Mike Ryan says.
Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year
In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.